Cargando…

Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment

BACKGROUND: Multiple sclerosis (MS) patients often suffer from gait impairment and fampridine is indicated to medically improve walking ability in this population. Patient characteristics, healthcare resource use, and costs of MS patients on fampridine treatment for 12 months in Germany were analyze...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ziemssen, Tjalf, Prosser, Christine, Haas, Jennifer Scarlet, Lee, Andrew, Braun, Sebastian, Landsman-Blumberg, Pamela, Kempel, Angela, Gleißner, Erika, Patel, Sarita, Huang, Ming-Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369011/ https://www.ncbi.nlm.nih.gov/pubmed/28347283 http://dx.doi.org/10.1186/s12883-017-0844-z

Ejemplares similares

Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany
por: Watson, Crystal, et al.
Publicado: (2017)

Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting
por: Rodriguez-Leal, Francisco Alejandro, et al.
Publicado: (2019)

Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting
por: Albrecht, Philipp, et al.
Publicado: (2018)

Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany
por: Becker, Veit, et al.
Publicado: (2018)

Fampridine and quality of life in individuals with multiple sclerosis
por: Sagawa, Yoshimasa, et al.
Publicado: (2016)

Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE
por: Hupperts, Raymond, et al.
Publicado: (2022)

Managing HAM/TSP with Fampridine
por: Menna-Barreto, M Marcio
Publicado: (2014)

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine
por: Hobart, Jeremy, et al.
Publicado: (2018)

Clinical, Neurophysiological, and MRI Markers of Fampridine Responsiveness in Multiple Sclerosis—An Explorative Study
por: Mamoei, Sepehr, et al.
Publicado: (2021)

Central motor conduction time may predict response to fampridine in patients with multiple sclerosis
por: Zeller, D, et al.
Publicado: (2014)

Sustained-Release Fampridine (4-Aminopyridine) in Multiple Sclerosis: Efficacy and Impact on Motor Function
por: Rabadi, Meheroz H., et al.
Publicado: (2013)

Lack of Attention to the Administration of Fampridine as a Symptomatic Drug in Iranian Multiple Sclerosis Patients
por: Moghadasi, Abdorreza Naser
Publicado: (2021)

Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol
por: Vormfelde, Stefan Viktor, et al.
Publicado: (2016)

Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine)
por: Keune, Philipp M., et al.
Publicado: (2015)

Cortical Excitability Measures May Predict Clinical Response to Fampridine in Patients with Multiple Sclerosis and Gait Impairment
por: Ahdab, Rechdi, et al.
Publicado: (2019)

The influence of the COVID-19 pandemic on the prescription of multiple sclerosis medication in Germany
por: Orschiedt, Jonathan, et al.
Publicado: (2023)

Digital Innovation in Multiple Sclerosis Management
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany
por: Canbay, Ali, et al.
Publicado: (2021)

Molecular biomarkers in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double‐blind, placebo‐controlled cross‐over trial
por: Kanhai, Kawita M. S., et al.
Publicado: (2019)

Gender disparities in health resource utilization in patients with relapsing–remitting multiple sclerosis: a prospective longitudinal real-world study with more than 2000 patients
por: Schriefer, Dirk, et al.
Publicado: (2020)

The importance of collecting structured clinical information on multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study
por: Ness, Nils-Henning, et al.
Publicado: (2020)

Why Cognitive–Cognitive Dual-Task Testing Assessment Should Be Implemented in Studies on Multiple Sclerosis and in Regular Clinical Practice
por: Beste, Christian, et al.
Publicado: (2020)

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial
por: Hupperts, Raymond, et al.
Publicado: (2016)

Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Data Resource Profile: The Multiple Sclerosis Documentation System 3D and AOK PLUS Linked Database (MSDS-AOK PLUS)
por: Ghiani, Marco, et al.
Publicado: (2023)

Data Collection in Multiple Sclerosis: The MSDS Approach
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety
por: Moser, Tobias, et al.
Publicado: (2022)

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
por: Akgün, Katja, et al.
Publicado: (2022)

Fatigue and Sleep in Multiple Sclerosis Patients: A Comparison of Self-Report and Performance-Based Measures
por: Paucke, Madlen, et al.
Publicado: (2018)

Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetate
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis
por: Proschmann, Undine, et al.
Publicado: (2021)

The need for a strategic therapeutic approach: multiple sclerosis in check
por: Inojosa, Hernan, et al.
Publicado: (2022)

Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine
por: Sola-Valls, Núria, et al.
Publicado: (2018)

Prolonged-release fampridine for the treatment of myoclonus after cervical myelitis: a case report
por: Müller, Mona Klara Ros, et al.
Publicado: (2022)

Dual-Tasking in Multiple Sclerosis – Implications for a Cognitive Screening Instrument
por: Beste, Christian, et al.
Publicado: (2018)

Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis
por: Woopen, Christina, et al.
Publicado: (2021)

Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qi0ft9c3v55fj3k9vobpiggd4v